Nephrology

CKD-associated gut dysbiosis linked to uremic toxins; microbiota therapies show modest biochemical gains.

CKD patients have reduced microbial diversity, loss of SCFA-producing taxa, and enrichment of proteolytic bacteria linked to uremic toxins. Gut-derived metabolites (IS, pCS, TMAO) are associated with oxidative stress, RAAS activation, and fibrogenesis in mechanistic studies. Randomized trials report modest biochemical effects: probiotics/synbiotics lowered BUN and CRP, and inulin 10 g/day reduced pCS by 25% and increased fecal butyrate. Most mechanistic data are animal or in vitro and human trials are heterogeneous and underpowered, so clinical outcome benefit remains unproven. 1

Smaller waitlists and faster offers associate with higher organ acceptance and lower pretransplant mortality.

Analysis of 1,268 program-years (220 programs) found higher offer acceptance with fewer waitlist patients. Each 100-patient decrease in waitlist size associated with a 1.4% increase in acceptance and a 1.4% decrease in pretransplant mortality. A higher percentage of patients receiving offers within 90 days correlated with a 24.0% increase in acceptance. Larger waitlists were linked to worse pretransplant outcomes, suggesting waitlist management may impact program performance. 2

Higher HbA1c variability predicts cardiovascular events and mortality in CKD cohorts.

Meta-analysis of eight cohorts (59,018 CKD patients) found higher HbA1c variability linked to increased cardiovascular events (HR 1.82, 95% CI 1.52–2.20). Higher variability also associated with greater all-cause mortality (HR 2.18, 95% CI 1.16–4.07), though heterogeneity was substantial. Association with CKD progression was inconclusive (HR 1.49, 95% CI 0.87–2.55) with wide prediction intervals. Observational cohorts limit causal inference, but HbA1c stability may be a pragmatic risk marker to monitor. 3